By Denny Jacob Gilead Sciences raised its outlook for 2023. The biopharmaceutical company forecast total sales between $26.7 billion and $26.9 billion versus its...
Boston Scientific BSX (NYSE: BSX) reported its Q3 results last month, with revenues and earnings beating the street estimates. However, we believe BSX stock...
Source: AdobeStock / JeanLuc Get your daily, bite-sized digest of crypto and blockchain-related news – investigating the stories flying under the radar of today’s...
The discussion of the recent short report on Brookfield Infrastructure Partners (NYSE:BIP) has largely subsided and the price of BIP units has recovered. The...